Inspection outcome reinforces company's compliance track record and strengthens its ability to serve regulated markets including the United States
SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers
These tests deliver results in 10–15 minutes at a cost of Rs 100–Rs 150, compared to conventional diagnostics which cost up to Rs 15,000
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
OneSource is the contract development and manufacturing organization (CDMO) partner for this product
Narasimhan’s appointment underscores the growing importance of AI in transforming drug discovery
The litigation involved multiple civil lawsuits alleging anti-competitive practices and violations of federal
The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics
The company said it is supporting the ongoing investigation and reiterated its commitment to patient safety.
Genome editing holds extraordinary promise for treating previously incurable genetic diseases
Subscribe To Our Newsletter & Stay Updated
